These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 14978513)

  • 21. Rebound anxiety in panic disorder patients treated with shorter-acting benzodiazepines.
    Herman JB; Brotman AW; Rosenbaum JF
    J Clin Psychiatry; 1987 Oct; 48 Suppl():22-8. PubMed ID: 2889722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action.
    Fawcett JA; Kravitz HM
    Pharmacotherapy; 1982; 2(5):243-54. PubMed ID: 6133268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg.
    Leufkens TR; Vermeeren A; Smink BE; van Ruitenbeek P; Ramaekers JG
    Psychopharmacology (Berl); 2007 May; 191(4):951-9. PubMed ID: 17219217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive style, alprazolam plasma levels, and treatment response in panic disorder.
    Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
    Depress Anxiety; 2008; 25(8):E18-26. PubMed ID: 17960759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study.
    Verster JC; Volkerts ER; Verbaten MN
    Neuropsychopharmacology; 2002 Aug; 27(2):260-9. PubMed ID: 12093599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam.
    Evans SM; Haney M; Levin FR; Foltin RW; Fischman MW
    Neuropsychopharmacology; 1998 Dec; 19(6):499-516. PubMed ID: 9803426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam.
    Bond AJ; Curran HV; Bruce MS; O'Sullivan G; Shine P
    J Affect Disord; 1995 Dec; 35(3):117-23. PubMed ID: 8749839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychopharmacological treatment of panic disorder and related states: a placebo controlled study of alprazolam.
    Swinson RP; Pecknold JC; Kuch K
    Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(2-3):105-13. PubMed ID: 3628823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam.
    Klein E
    J Clin Psychiatry; 2002; 63 Suppl 14():27-33. PubMed ID: 12562116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder.
    Gladsjo JA; Rapaport MH; McKinney R; Auerbach M; Hahn T; Rabin A; Oliver T; Haze A; Judd LL
    J Clin Psychopharmacol; 2001 Apr; 21(2):131-8. PubMed ID: 11270908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alprazolam-reinforced medication use in outpatients with anxiety.
    Roache JD; Stanley MA; Creson DR; Shah NN; Meisch RA
    Drug Alcohol Depend; 1997 May; 45(3):143-55. PubMed ID: 9179516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depression and panic anxiety: the effect of depressive co-morbidity on response to drug treatment of patients with panic disorder and agoraphobia.
    Klerman GL
    J Psychiatr Res; 1990; 24 Suppl 2():27-41. PubMed ID: 1980697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subjective experience and attitudes towards participation in clinical trials among patients with anxiety disorders.
    Klein E; Malel D; Zilberman I; Lenox RH
    Isr J Psychiatry Relat Sci; 1997; 34(4):265-9. PubMed ID: 9409083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alprazolam in panic disorder: a retrospective analysis.
    Shelton RC; Harvey DS; Stewart PM; Loosen PT
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 May; 17(3):423-34. PubMed ID: 8475324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial.
    Taylor CB; Hayward C; King R; Ehlers A; Margraf J; Maddock R; Clark D; Roth WT; Agras WS
    J Clin Psychopharmacol; 1990 Apr; 10(2):112-8. PubMed ID: 2187912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alprazolam in the treatment of panic disorders.
    Liebowitz MR; Fyer AJ; Gorman JM; Campeas R; Levin A; Davies SR; Goetz D; Klein DF
    J Clin Psychopharmacol; 1986 Feb; 6(1):13-20. PubMed ID: 2869059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis.
    Boyer W
    Int Clin Psychopharmacol; 1995 Mar; 10(1):45-9. PubMed ID: 7622804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group.
    Möller HJ; Volz HP; Reimann IW; Stoll KD
    J Clin Psychopharmacol; 2001 Feb; 21(1):59-65. PubMed ID: 11199949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The efficacy of alprazolam in the therapy of panic disorders].
    Diukova GM; Vorob'eva OV; Petrova EP; Smirnov SV; Tumalaeva ZN
    Zh Nevrol Psikhiatr Im S S Korsakova; 1995; 95(4):9-13. PubMed ID: 8533521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.
    Ballenger JC; Burrows GD; DuPont RL; Lesser IM; Noyes R; Pecknold JC; Rifkin A; Swinson RP
    Arch Gen Psychiatry; 1988 May; 45(5):413-22. PubMed ID: 3282478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.